Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

About this update from Enveric Biosciences, Inc.

Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice (GLP) studies will evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission. The studies will include a standard battery of tests in compliance with the International Council for Harmonisation (ICH) S2(R1) guidelines including the Bacterial Reverse Mutation Assay/Ames Test and the Micronucleus Assay. “Initiating these genotoxicity studies marks a significant milestone in the development of EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “With the recent Executive Order signed by the President on April 18, 2026, the landscape has shifted, potentially expediting research for compounds in the psychedelic and neuroplastogen field. Our preclinical studies are pivotal to ensuring we continue to meet the highest standards of safety as we progress towards first-in-human Phase 1 clinical trials.” About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit www.enveric.com. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities...

View stock analysis, news, and events for Enveric Biosciences, Inc.